Exosome-derived lnc-FAM72D-3 promotes lenvatinib resistance by remodeling hepatocellular carcinoma cytoskeleton via MBNL1/FAK axis
Drug Resistance Updates · 2025
DOI: 10.1016/j.drup.2025.101271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2025. Verfasst von Mingbo Cao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, RNA, Long Noncoding, Phenylurea Compounds. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Sun Yat-sen University, Basic and Applied Basic Research Foundation of Guangdong Province, Scientific and Technological Planning Project of Guangzhou City.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China.
- Department of General Surgery, Qilu Hospital, Shandong University, Jinan China.
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
- Biotherapy Centre, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China. Electronic address: zhangq27@mail.sysu.edu.cn.
- Department of Hepatobiliary Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China. Electronic address: dengmeih@mail.sysu.edu.cn.
- Department of Hepatobiliary & Pancreatic Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China; Biotherapy Centre, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 51063…
Förderung
- Sun Yat-sen University
- Basic and Applied Basic Research Foundation of Guangdong Province
- Scientific and Technological Planning Project of Guangzhou City
- Beijing Xisike Clinical Oncology Research Foundation
Zitieren
APA
Cao, M., Li, Y., Su, X., Tang, Y., Ren, Y., Luo, J., Yuan, F., Yang, G., He, Z., Shi, Z., Hu, Z., Liang, G., Zhang, Q., Deng, M., Yao, Z., & Lin, N. (2025). Exosome-derived lnc-FAM72D-3 promotes lenvatinib resistance by remodeling hepatocellular carcinoma cytoskeleton via MBNL1/FAK axis. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101271
Vancouver
Cao M, Li Y, Su X, Tang Y, Ren Y, Luo J, et al. Exosome-derived lnc-FAM72D-3 promotes lenvatinib resistance by remodeling hepatocellular carcinoma cytoskeleton via MBNL1/FAK axis. Drug Resistance Updates. 2025. doi:10.1016/j.drup.2025.101271
BibTeX
@article{Cao2025,
author = {Cao, Mingbo and Li, Yuxuan and Su, Xiaorui and Tang, Yongchang and Ren, Yupeng and Luo, Jing and Yuan, Feng and Yang, Gaoyuan and He, Zhiwei and Shi, Zheng and Hu, Ziyi and Liang, Guirong and Zhang, Qi and Deng, Meihai and Yao, Zhicheng and Lin, Nan},
title = {Exosome-derived lnc-FAM72D-3 promotes lenvatinib resistance by remodeling hepatocellular carcinoma cytoskeleton via MBNL1/FAK axis},
journal = {Drug Resistance Updates},
year = {2025},
doi = {10.1016/j.drup.2025.101271}
}
EUVIMED